{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T11:00:58Z","timestamp":1784977258008,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation of Chongqing, China","award":["CSTB2022NSCQ-MSX1207"],"award-info":[{"award-number":["CSTB2022NSCQ-MSX1207"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04247-2","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T15:30:24Z","timestamp":1771342224000},"page":"3508-3515","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal nanoparticle-formulated and conventional anticancer irinotecan"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3855-7969","authenticated-orcid":false,"given":"Chunyong","family":"Xia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenming","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"14","key":"4247_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21144919","volume":"21","author":"M Kciuk","year":"2020","unstructured":"Kciuk M, Marciniak B, Kontek R. Irinotecan-still an important player in cancer chemotherapy: a comprehensive overview. Int J Mol Sci. 2020;21(14):4919.","journal-title":"Int J Mol Sci"},{"key":"4247_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104398","volume":"148","author":"C Bailly","year":"2019","unstructured":"Bailly C. Irinotecan: 25 years of cancer treatment. Pharmacol Res. 2019;148:104398.","journal-title":"Pharmacol Res"},{"issue":"16","key":"4247_CR3","first-page":"4187","volume":"51","author":"Y Kawato","year":"1991","unstructured":"Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991;51(16):4187\u201391.","journal-title":"Cancer Res"},{"issue":"4","key":"4247_CR4","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1200\/JCO.1996.14.4.1128","volume":"14","author":"ML Rothenberg","year":"1996","unstructured":"Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14(4):1128\u201335.","journal-title":"J Clin Oncol"},{"key":"4247_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2024.176614","volume":"974","author":"S Xu","year":"2024","unstructured":"Xu S, Lan H, Huang C, Ge X, Zhu J. Mechanisms and emerging strategies for irinotecan-induced diarrhea. Eur J Pharmacol. 2024;974:176614.","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"4247_CR6","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","volume":"66","author":"DC Drummond","year":"2006","unstructured":"Drummond DC, Noble CO, Guo Z, Hong K, Park JW, Kirpotin DB. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy. Cancer Res. 2006;66(6):3271\u20137.","journal-title":"Cancer Res"},{"key":"4247_CR7","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2018.12.007","volume":"108","author":"A Wang-Gillam","year":"2019","unstructured":"Wang-Gillam A, Hubner RA, Siveke JT, Von Hoff DD, Belanger B, de Jong FA, et al. NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: final overall survival analysis and characteristics of long-term survivors. Eur J Cancer. 2019;108:78\u201387.","journal-title":"Eur J Cancer"},{"issue":"9","key":"4247_CR8","doi-asserted-by":"publisher","first-page":"4132","DOI":"10.1021\/acs.molpharmaceut.8b00540","volume":"15","author":"N Bernards","year":"2018","unstructured":"Bernards N, Ventura M, Fricke IB, Hendriks BS, Fitzgerald J, Lee H, et al. Liposomal irinotecan achieves significant survival and tumor burden control in a triple negative breast cancer model of spontaneous metastasis. Mol Pharm. 2018;15(9):4132\u20138.","journal-title":"Mol Pharm"},{"issue":"10","key":"4247_CR9","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1007\/s40265-020-01336-6","volume":"80","author":"JE Frampton","year":"2020","unstructured":"Frampton JE. Liposomal irinotecan: a review in metastatic pancreatic adenocarcinoma. Drugs. 2020;80(10):1007\u201318.","journal-title":"Drugs"},{"issue":"19","key":"4247_CR10","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1200\/JCO.23.02110","volume":"42","author":"DR Spigel","year":"2024","unstructured":"Spigel DR, Dowlati A, Chen Y, Navarro A, Yang JC, Stojanovic G, et al. RESILIENT part 2: a randomized, open-label phase III study of liposomal irinotecan versus Topotecan in adults with relapsed small cell lung cancer. J Clin Oncol. 2024;42(19):2317\u201326.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4247_CR11","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/JS9.0000000000002194","volume":"111","author":"H Liu","year":"2025","unstructured":"Liu H, Yang Q, Li Z, Yan S, Ming S. Systematic analysis of sugammadex-related adverse drug reaction signals using FAERS database. Int J Surg. 2025;111(2):1988\u201394.","journal-title":"Int J Surg"},{"issue":"2","key":"4247_CR12","doi-asserted-by":"publisher","first-page":"e153","DOI":"10.1111\/jdv.20197","volume":"39","author":"H Godfrey","year":"2025","unstructured":"Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025;39(2):e153\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"4247_CR13","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s15010-024-02248-3","volume":"52","author":"X Zhang","year":"2024","unstructured":"Zhang X, Jiang Y, Guo Y, Zhou W, Qiao W, Zhu H, et al. Safety evaluation of ceftazidime\/avibactam based on FAERS database. Infection. 2024;52(6):2195\u2013205.","journal-title":"Infection"},{"issue":"1","key":"4247_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-92330-z","volume":"15","author":"H Gao","year":"2025","unstructured":"Gao H, Cao L, Liu C. Analysis and mining of Dupilumab adverse events based on FAERS database. Sci Rep. 2025;15(1):8597.","journal-title":"Sci Rep"},{"issue":"1","key":"4247_CR15","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1080\/14686996.2019.1627174","volume":"20","author":"M Mohamed","year":"2019","unstructured":"Mohamed M, Abu Lila AS, Shimizu T, Alaaeldin E, Hussein A, Sarhan HA, et al. PEGylated liposomes: immunological responses. Sci Technol Adv Mater. 2019;20(1):710\u201324.","journal-title":"Sci Technol Adv Mater"},{"issue":"1","key":"4247_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-55090-4","volume":"16","author":"Y Fan","year":"2025","unstructured":"Fan Y, Zhang Q, Yan M, Qu X, Yin Y, Sun T, et al. Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after \u2265 2 prior lines of chemotherapy: a phase Ib study. Nat Commun. 2025;16(1):3.","journal-title":"Nat Commun"},{"issue":"5","key":"4247_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","volume":"9","author":"J Hyung","year":"2023","unstructured":"Hyung J, Kim I, Kim KP, Ryoo BY, Jeong JH, Kang MJ, et al. Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: the phase 2b NIFTY randomized clinical trial. JAMA Oncol. 2023;9(5):692\u20139.","journal-title":"JAMA Oncol"},{"issue":"2","key":"4247_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics9020012","volume":"9","author":"U Bulbake","year":"2017","unstructured":"Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.","journal-title":"Pharmaceutics"},{"issue":"9","key":"4247_CR19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000033005","volume":"102","author":"S Zhang","year":"2023","unstructured":"Zhang S, Yang J, Zhan H, Yang B, Rong P, Luo Y, et al. Incidence and non-genetic risk factors of irinotecan-induced severe neutropenia in Chinese adult inpatients. Medicine. 2023;102(9):e33005.","journal-title":"Medicine"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04247-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04247-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T10:28:55Z","timestamp":1784975335000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04247-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":19,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4247"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04247-2","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The FAERS database contains anonymized patient information. The Hospital Ethics Committee has confirmed that no ethical approval was required.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}